Success with Crystal Bank Protein Structure Resource
News Nov 25, 2005
Sareum Holdings plc has announced the latest developments with its "Crystal Bank" resource of rapidly accessible protein structures first announced in September 2005.
To date, Sareum has signed three fee-for-service collaborations involving Crystal Bank proteins, providing an important source of revenues to support its in-house research programs.
Sareum’s Crystal Bank now comprises 16 therapeutically relevant proteins which are the targets for research into many important diseases including cancer, inflammation and metabolic disorders.
Example structures include GSK3 beta, p38 MAP kinase, CDK2/Cyclin A2, Zap-70, Erk2 and PPAR delta.
Crystal Bank protein structures are available to pharmaceutical and biotechnology company clients in complex with their potential drug candidates on a fee-for-service basis.
This information assists clients in accelerating their drug discovery by providing a valuable insight into the nature of the interaction between these potential drug candidates and their target proteins.
Commenting on the announcement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are extremely pleased to announce this growing list of available protein structures and the commercial results achieved so far."
"This success demonstrates our expertise in rapidly providing novel and valuable protein structural information that will advance research into novel drug treatments."
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019